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Advances in biotechnology in the last decade have been
tremendous. The technologies used in molecular biology,
genetics, and biochemistry have catapulted our understand-
ing of cellular processes and have led to several changes in
howwe practicemedicine; and the coming years will be even
more eventful. Not only canwe now detect genetic mutations
and achieve results in a fraction of the time, but we can do this
using smaller tissue samples than ever before. Together, these
capacities have enabled increasingly personalized therapeu-
tic approaches for patients with colorectal cancer (CRC).
In the traditional paradigm of oncologic treatment strate-
gies, three optionswere available for treating cancer: surgery,
cytotoxic chemotherapy, and radiation. The choice of ideal
treatment was made based upon the organ of origin, the
histologic type of malignancy described, and the stage of the
disease. In such a paradigm, all nonmetastatic colon cancers
have surgery, and all stage III patients receive the same
adjuvant chemotherapeutic agents, resulting in heteroge-
neous responses: some do well and some recur. We are
rapidly closing in on using each patient’s own unique genetic
and tumor profile to help understand these discrepancies and
inform medical decision-making, what is termed “personal-
ized medicine.” As we learn more about the genetic changes
associatedwith CRC, we are also learning ways inwhich these
mutations can be used to diagnose, prognosticate outcomes,
and measure responses to treatments.
The term “biomarker” is somewhat difficult to define. At its
essence, it is any biological substrate that can be detected, which
is then used to help guide medical decision-making. Current
biomarkers in routine clinical use today for CRC includemeasur-
ing serum carcinoembryonic antigen (CEA) and detecting mis-
match repair (MMR) gene and KRASmutations in tumor tissues.
Our goal is to review the current state of the science on
biomarkers as it relates to CRC. We will discuss the use of CEA
for monitoring of recurrence, the role of genetic testing in
guiding surveillance, and treatment decisions and how genetic
mutations may predict response to chemotherapy and out-
comes.Wewill also briefly review how biomarkers can function
as liquid biopsies and explore several new substrates that are
currently under investigation. Given the pace of advancements
inmolecular biology, genetics, and amplification technologies, it
is highly likely that in our careerswe could do things only seen in
the movies: from a single drop of blood we could diagnose the
presence of CRC, understand precisely the genetic mutations
present, how they impact outcomes and respond to treatment,
and even follow that profile as it changes over time.
Carcinoembryonic Antigen
The standard serum biomarker in use today for CRC is CEA. It
is a superfamily of glycoproteins found on cell membranes
that play an important role in cell recognition and adhesion. It
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is thought to be intimately involved in the ability of CRC cells
to metastasize; colorectal adenocarcinoma produces larger
amounts of this protein as a result of alterations in posttran-
scriptional regulation.1,2 Interestingly, most newly diagnosed
patients present with normal levels as it is cleared in the liver
before entering the systemic circulation, though in cases of
distal cancers alternate circulation patterns through the
internal iliac vessels may be associated with high levels.2
Most modern assays for detecting CEA use a monoclonal
technique that has a low false-positive rate; however, it can
still be elevated in several disease states such as tobacco use,
liver disease, and renal dysfunction.2
Unfortunately, CEA has little utility as a screening tool for
diagnosing new CRCs due to poor sensitivity and specificity,
particularly in early-stage cancer.2 Fletcher calculated that if
CEAwere used to screen patients for CRC, at a sensitivity and
specificity for early-stage disease of 40 and 90%, respectively,
there would be 250 false-positive tests while missing 60% of
cancers in asymptomatic patients.3Other biomarkers, such as
CA 19–9 and CA 242, have fared no better and currently no
serum test is recommended as a screening tool for diagnosing
CRC.4,5
While CEAmaybe a poor candidate to assist in screening or
diagnosis, it has some utility in predicting prognosis and
monitoring for recurrence; elevated levels have been shown
to correlate with poor outcomes and might be a useful
strategy for defining patients at higher risk of recurrence.1
Preoperative CEA levels also serve as a benchmark to follow
treatment outcomes—levels that do not fall within 6 weeks of
resection are concerning for residual disease, either local or
metastatic. Serial measurements after curative resection can
also give an early warning of recurrence or metastatic dis-
ease; it is the most frequent indicator of recurrence in
asymptomatic patients, is more cost-effective than radiology
for detecting curable recurrent disease, is highly sensitive for
liver metastases, and can improve survival when included as
part of an intensive surveillance plan.1,6,7 Using CEA to detect
recurrence has been shown to provide 5 months lead time
before developing other cancer-related symptoms, though
this has not been shown to result in improved survival.8
Current National Comprehensive Cancer Network (NCCN)
recommendations include measuring CEA levels at diagnosis
and every 3 to 6months for thefirst 2 years, followed byevery
6 months for the next 3 years in all patients with stage I to III
CRC who would be candidates for further treatment if de-
tected.9 An increase of 30% above baseline is generally
considered significant enough to warrant further evaluation,
though no widely accepted definition is reported in any
recommendation.1
For patients with metastatic disease, CEA changes during
treatment can indicate response to therapy.While an elevated
preoperative CEA is associated with poor outcomes in all
patients, a fall in the CEA to normal levels after complete
hepatic disease resection is highly predictive of improved
survival.10 Furthermore, CEA is a good biomarker when
monitoring response to chemotherapy; the predictive value
of a rising CEA during chemotherapy is so suggestive of
progression that further imaging and testing may not be
needed before changing treatment regimens.4,11 Serial CEA
measurements every 2 to 3 months while on chemotherapy
are beneficial as persistent rises can detect progression even
before it may be apparent on imaging; thus, ineffective
regimens can be changed quickly, reducing costs and improv-
ing quality of life.4
Despite the demonstrated benefits of using CEA as a
biomarker for recurrence and response to treatment, there
are some significant limitations. Notably, it has low sensitivity
and specificity for early stage CRCs, so it is not only a poor
screening tool as a noninvasive alternative to colonoscopy, it
has limited ability to prognosticate in patients with early-
stage disease who have normal levels—a significant propor-
tion of thosewith the disease. It can also be falsely elevated in
several common scenarios, such as patients who smoke and
have either renal or liver dysfunction; therefore, a high level
in an otherwise asymptomatic patient still demands further
diagnostic testing. In addition, there is some concern that
serial testing after curative treatment is not cost effective in
terms of lives saved and improved survival.2While using CEA
as a biomarker has some advantages—its easily measured via
a serum test and can be repeated frequentlywith little impact
on the patient—it also has some significant drawbacks;
therefore, the search for better substrates continues.
Indications for Genetic Testing
Polyposis Syndromes
CRC is a heterogeneous disease. Most CRC occurs sporadically,
but approximately 30% of cases demonstrate a familial predis-
position, and a positive family history in unaffected persons
doubles their risk of developing CRC.12 However, only one-third
of patients with a family history have identifiable germline
mutations. Given their differential risk profiles, and the benefit
of initiating early screening protocols in affected persons, the
importance of identification of patients with hereditary syn-
dromes is well-recognized. Accordingly, well-defined clinical
parameters exist for selecting patients who should undergo
genetic testing for suspected hereditary syndromes.13,14
Several polyposis syndromes have been linked to specific
genetic mutations, thus any patient presenting with more
than 10 polyps, hamartomatous polyps, or polyps at a young
age (under 30 years), should prompt genetic evaluation.
While the involved genes are known for many of these
diseases, de novo mutations within a family can occur, so
clinical suspicion outside of family history should prompt
evaluation and can be enough to establish the diagnosis as the
patient may have a mutation not identifiable by conventional
methods.15,16 The most commonly occurring hereditary syn-
drome is familial adenomatous polyposis. There are several
mutations that occur in the APC gene, each with a known
associated phenotype that gives rise to several presentations
including an attenuated form.17,18 Another similar polyposis
syndrome has been described that involves an autosomal
recessive mutation in the MUTYH gene, known as MUTYH-
associated polyposis (MAP). Hamartomatous polyposis syn-
dromes are much less common and de novo mutations occur
as well, so clinical suspicion is paramount (see ►Table 1).
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Lynch Syndrome
Lynch syndrome (LS), the most common heritable form of
CRC, it is an autosomal dominant inherited disease with
variable penetrance, and accounts for approximately 3% of
all CRCs.19,20 It generally results from inheritance of germline
mutations in MMR genes, though rarely de novo mutations,
which rise at a rate of about 2%, can also cause the syn-
drome.21 Patients with LS can be identified using several
strategies. Traditional clinical criteria for identifying persons
at risk for LS, such as Amsterdam criteria and Bethesda
guidelines, set forth parameters primarily based on family
history and age at diagnosis. Both have undergone modifica-
tions in the efforts of improving sensitivity and specificity.
Computational models, such as MMRpredict (Edinburgh,
Scotland, UK), offer better sensitivity and specificity, but
are less convenient to use in everyday practice.22
While these methods can be used to recognize patients at
risk for LS, tumor testing confirms the diagnosis. The Center
for Disease Control recommendations support the use of
universal genetic screening for the presence of common
mutations in MMR genes for all patients with newly diag-
nosed CRC.23 However, the utilization of resources with
universal genetic testing is significant, and this guideline is
not collectively endorsed. Alternative recommendations in-
clude screening for patients with CRC under the age of
70 years and those over 70 years with a family history
concerning for LS.24,25
Strategies to assess MMR deficiency use either immuno-
histochemistry (IHC) to identify impaired protein expression
of the four MMR genes commonly mutated in LS (MLH1,
MSH2, MSH6, PMS2), or polymerase chain reaction (PCR) to
detect microsatellite instability (MSI), which suggests im-
properly functioning MMR proteins. Results of IHC and PCR
generally agree, however, IHC is slightly less sensitive and
specific. Even so, due to the increased availability of IHC, and
its cost savings in comparison to PCR, it is often the first step
in tumor analysis.26,27 Once an MMR protein deficiency is
identified, testing with PCR can confirm MSI. This involves
testing five markers, known as the Bethesda panel (BAT 25,
BAT 26, D5S346, D2S123, and D17S250), though other com-
mercially available panels are widely used.28,29 MSI tumors
are regarded as MSI-H (high) if > 30% of the markers are
mutated, MSI-L (low) if at least one and < 30% of the markers
aremutated, andmicrosatellite stable (MSS) if nomarkers are
mutated.30 To determine the etiology of MSI in patients
without a clear family history of LS, further analysis of the
pattern of protein loss can be useful. In patients with a MLH1
deficiency, testing for BRAF mutations and MLH1 hyperme-
thylation should follow, as these are often seen in sporadic
CRC with MSI but rarely seen in LS, which is associated with
direct mutations in MLH1 or MSH2.31–33 Alternatively, if loss
of MLH2 and/or MSH6 protein occurs, genetic testing should
evaluate MSH2, EpCAM, and MSH6.24,34
Until recently, there has been little clinical utility for
understanding the genetics of sporadic CRC. Over the last
decade, advances in molecular techniques and genomic pro-
filing have improved our understanding of cellular processes,
allowing for the development and approval of several tar-
geted therapies for use in the CRC. This has resulted in an
explosion of scientific interest in establishing genetic bio-
markers with prognostic and predictive value that can be
used to help guide treatment decisions.
Mutation Analysis to Guide Treatment
Targeted Therapy in Metastatic Colorectal Cancer
The development of several “targeted therapies” for use in
metastatic CRC has led to an increasing drive to use each
patient’s unique tumor mutational profile to help inform
treatment choices (see ►Table 2). This is the beginning of
personalized medicine—neither two persons, nor do two
tumor cells harbor the same profile. Tumor mutation profiles
can even change over time as new mutations accumulate or
respond to treatment. The beginning of this was the under-
standing of the impact of KRAS and NRAS mutations. The
Table 2 Clinical relevance of colorectal cancer genetic
mutations
Mutated
gene
Clinical impact of mutation
KRAS Lack of response to anti-EGFR targeted
therapy
NRAS Possible limited benefit of anti-EGFR
targeted therapy
BRAF Poor prognostic indicator
MMR with
MSI
Limited benefit of adjuvant chemotherapy
in Stage II
Good prognostic indicator
LOH 18q/CIN Possible resistance to fluorouracil
Top 1 Possible increased response to irinotecan
ERCC1 Possible increased response to oxaliplatin
or fluorouracil
UGT1A Increased risk of toxicity from irinotecan
DPYD Increased toxicity with fluorouracil
Abbreviation: EGFR, epidermal growth factor receptor; LOH, loss of
heterozygosity.
Table 1 Heritable mutations in colorectal cancer
Syndrome Mutated
gene
Inheritance pattern
FAP, attenuated FAP APC Autosomal dominant
MAP MUTYH Autosomal recessive
Peutz–Jeghers STK11, LKB1 Autosomal dominant
Juvenile polyposis SMAD4,
BRMP1A
Autosomal dominant
Cowden, Bannayan–
Riley–Ruvalcaba
PTEN Autosomal dominant
Abbreviations: FAP, familial adenomatous polyposis; MAP, MUTYH-as-
sociated polyposis.
Source: Table adapted from Syngal et al.14
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protein products of these genes are involved in intracellular
signaling pathways that promote cell growth and develop-
ment via MAP kinase activation. Mutations in these genes
result in constitutive activation of the MAPK pathway and are
present in 40% of CRCs at KRAS exon 2 (codons 12 and
13).35,36 Patients with KRASmutations do not respond to the
targeted anti-epidermal growth factor receptor (anti-EGFR)
therapy, including cetuximab and panitumumab,which block
activation of the pathway in patients with wild type (WT)
KRAS genes. Additionally, and perhaps more importantly,
patients with KRAS mutations have been shown to have
worse outcomes when given anti-EGFR-targeted chemother-
apy, highlighting the importance of assessing KRAS status
before the initiation of these therapies.37,38 For those patients
with metastatic CRC and no KRAS mutations, anti-EGFR
therapy can confer a significant survival benefit.39
Though eliminating patients with known mutations in
KRAS results in improved response rates to EGFR-targeted
therapies in combination with chemotherapy, still only ap-
proximately 10% of KRASWTpatients respond to cetuximab as
monotherapy, suggesting the need for further efforts to im-
prove patient selection by better identification of those who
will respond to this therapy.38,40–42 Accordingly, investigators
have become increasingly interested in studies revealing a lack
of response among tumors with other RAS family mutations,
specifically on the NRAS gene, designated “extended RAS” or
“expanded RAS” mutations.43–45 Nearly 20% of KRAS WT
tumors bear one of these mutations and patients with these
mutations may also have limited benefit from anti-EGFR
therapies, suggesting an opportunity to further improve pa-
tient selection by excluding a significant portion of KRAS WT,
who would be unlikely to respond to anti-EGFR therapy.43,45
While testing forKRASmutations in codons 12 and13 iswidely
recommended to help guide selection of chemotherapeutic
agents, testing for other KRAS and NRAS mutations is more
controversial.25,46 Still, current NCCN recommendations state
that patients with any KRAS or NRAS mutation should not be
treated with cetuximab or panitumumab.25
BRAF is another important protein in the MAP kinase
pathway. Mutations in BRAF occur in approximately 15% of
CRC, and in contrast toKRAS, evidence concerning the efficacy
of anti-EGFR therapy in BRAF mutated CRC is conflicting.
Several studies show no benefit of anti-EGFR therapy in
patients with BRAF mutations.35,47,48 However, pooled data
from the CRYSTAL and OPUS trials suggest that BRAF status
does not predict a response to anti-EGFR therapy.49 Some of
the difficulty in arriving at definitive conclusions stems from
the relatively low incidence of BRAF mutations in patients
with CRC.35,36 The prognostic significance of BRAFmutations
is more certain, as patients with this mutation have consis-
tently been shown to have poor outcomes in relation to those
with WT BRAF, with reduced overall survival and progres-
sion-free survival.44,50,51 Current NCCN recommendations
include testing of tumors for BRAF mutations in stage IV
disease, though this is of prognostic value only.25 Even so,
testing in metastatic patients, particularly those who have
failed other chemotherapy regimens, may yield additional
benefit to patients in terms of identifying thosewhomight be
eligible to participate in clinical trials with BRAF inhibitors,
which are likely to be of more clinical utility.43
Microsatellite Instability in Stage II Colon Cancer
MSI occurs in about 15% of sporadic KRAS WT CRCs. It is
associated with right-sided lesions and poorly differentiated,
mucinous histology.52,53 MSI testing for the purposes of identi-
fying patients with LS should be performed according to previ-
ously described guidelines. Additionally, the NCCN recommends
MSI testing of all tumors in patients with Stage II disease. MSI
indicates improved prognosis in comparison toMSS tumors and
MSI status can also be used to aid in assessing the likelihood that
patients will benefit from adjuvant chemotherapy.25
Despite the predominance of poorly differentiated histolo-
gy among patients with MSI tumors, these patients tend to
have improved outcomes and a decreased likelihood of metas-
tases in comparison to patients with MSS tumors.54 In this
respect, MSI is regarded as a strong positive prognostic
indicator.55,56 There is evidence to support that patients
with MSI tumors and Stage II/III CRC do not have the same
improvement in disease-free survival and overall survivalwith
adjuvant fluorouracil (5-FU)-based therapy as compared with
their MSS counterparts.52,53 Furthermore, the use of 5-FU in
MSI patients with Stage II CRC has been associated with
adverse outcomes.53 However, these results were found in
the setting of regimens lacking oxaliplatin, an agent almost
universally used in the adjuvant treatment of CRC today. More
recent data from randomized trials (PETACC 3 and QUASAR)
have not confirmed these findings.57,58 Taken together, it is
currently recommended that tumors from patients with stage
II CRC be tested forMSI. Decisions about whether patientswith
Stage II CRC andMSI receive 5-FU-based chemotherapy should
be individually tailored and based on risk assessment.25 The
same trend is not seen in stage III CRC, where a clear survival
benefit is seen with adjuvant chemotherapy in all patients.59
Chromosomal Instability, Topoisomerase I, and
Excision Repair Cross-Complementing Gene 1
Polymorphisms
Chromosomal instability (CIN) describes a state of high rates
of gains and losses of chromosomes within tumors. The cause
of CIN is unknown, but loss of heterozygosity (LOH) is a
hallmark feature and LOH at 18q has generated attention due
to its possible association with outcomes.60,61 Additionally,
there is some limited evidence to suggest that CIN, in general,
may be indicative of resistance to both taxols and 5-FU.62,63
Topoisomerases allow for DNAunwinding, a process that is
imperative for DNA replication and upregulated in the CRC.64
The cytotoxic chemotherapeutic agent irinotecan binds and
stabilizes the topoisomerase I (Top I)–DNA complex, prevent-
ing further DNA replication.65 Accordingly, the UK MRC
FOCUS trial showed that Top I overexpression predicts a
response to irinotecan and possibly oxaliplatin, though this
could not be verified in another study.66,67 A similar story is
seen for another gene, excision repair cross-complementing
(ERCC1), which encodes the ERCC-1 protein and is responsible
for repairing double strand breaks and cross-linking errors in
DNA.64 ERCC-1 deficiency is common in a CRC and can result
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from either genetic mutation or promoter methylation.67
ERCC-1 deficiency has been noted to predict response to
oxaliplatin or 5-FU-based chemotherapy, but this could not
be confirmed in other retrospective analyses.68,69 A deal of
additional research evaluating the utility of the above bio-
markers is needed before widespread routine clinical use can
be recommended.
Predicting Chemotherapy Toxicity
The uridine diphosphate glucuronosyltransferase 1A (UGT1A)
gene is located on chromosome 2q37. The gene transcribes
several enzymes, among them, UGT1A1 is commonly known for
its role in the glucuronidation of bilirubin and a mutation here
can result in increased concentrations of the activemetabolite of
irinotecan, thus increasing tumor responsiveness to this regimen
in the presence of the mutation. However, this increased cyto-
toxicity also increases the risk of adverse reactions, such as
neutropenia and diarrhea. Despite the known risk of toxicity in
patients with the mutation, the recommendations do not cur-
rently endorse routine testing. Rather, they advise dose reduc-
tions in the setting of adverse reactions.70 Dihydropyrimidine
dehydrogenase (DPD) deficiencycan also lead to chemotherapy-
related toxicity as it is the enzyme responsible formetabolism of
5-FU. Deficiency of this enzyme is present in 3 to 5% of the
population and is associated with severe adverse effects in
response to 5-FU-based chemotherapy.69,71Deficiencygenerally
rises through mutations in the dihydropyrimidine dehydroge-
nase gene (DPYD, mapped to chromosome 1p22) and patients
who are homozygous for themutant DPYD allele can have lethal
reactions to5-FU.72Despite thepropensity for patientswithDPD
deficiency to develop toxicity in response to 5-FU, its association
with response to therapy is uncertain. Given decreased adverse
effects with newer dosing regimens and the lack of solid
evidence to support its ability to predict response to therapy,
testing for DPD deficiency is not currently standard.73,74
In addition to DPD, mutations in other enzymes partici-
pating in pyrimidine metabolism, such as thymidylate syn-
thase and methylenetetrahydrofolate reductase, may predict
clinical outcome, response, and toxicity to 5-FU. With regard
to biological therapies, investigators have been interested in
the utility of PI3K and PTEN to predict response to anti-EGFR
therapy.75 Similarly, others are exploring the capacity for
soluble vascular endothelial growth factor (VEGF), plasma
VEGF, and tumor VEGF to predict responses to treatment with
anti-VEGF.74 The clinical validity of these markers and more
are yet to be defined.
Multigene Assays
Several multigene assays are available for the purposes of risk
stratification. Oncotype DX (Genemics Health Inc., Redwood
City, CA), ColoPrint (Agendia NV, Amsterdam, Netherlands),
and ColDx (Almac, Craigavon, Ireland) each offer genetic panels
to aid in predicting recurrence of CRC.25 The 12 gene assay,
Oncotype DX, was developed using data from NSABP studies
and the Cleveland Clinic. Its predictive value, in terms of
establishing a recurrence score for patients with Stage II and
Stage III CRC, was validated in studies using tissue and data
gathered in both the QUASAR and NSABP-07 trials.76–78 The
ColoPrint is a similar panel, with 18 genes. In a retrospective
cohort study comparing ColoPrint to clinical risk factors out-
lined by NCCN guidelines, ColoPrint was more accurate at
predicting recurrence of stage II MSS CRC. The study was
unable to show a benefit of chemotherapy according to risk
stratification, however, this would best be appreciated in a
randomized trial that is adequately powered to do so.79 Finally,
ColDx is amicroarray-based assaywas validated in its ability to
assess recurrence risk in stage II CRC using specimens and data
gathered from CALGB 9581.80 Despite the capacity of these
assays to determine risk of recurrence, no test has displayed
the ability to predict a response to chemotherapy, therefore,
the true impact of these diagnostics on oncologic outcomes is
uncertain, and the utility of these assays in assistance with
clinical decision-making has yet to be determined.25
Limitations of Current Biomarkers and
Future Possibilities
As of today, all analyses of tumor characteristics are depen-
dent upon invasive biopsy. This includes evaluation of the
specific tumor type and histologic features as well as genetic
profile. Whether tissue is collected via endoscopic or percu-
taneous biopsy, or from a surgical specimen, a reasonably
large volume of tissue is needed for interrogation. In most
cases, these specimens are collected at the time of diagnosis,
but performing the tests evaluating some biomarkers, such as
KRAS, may be delayed until the patient recurs withmetastatic
disease. This sequencing may pose several problems. First,
CRC is a heterogeneous disease with several distinct path-
ways to progression, thus each person and even each cell has
the potential to harbor a different profile of mutations.81,82
Second, tumor molecular profiles change over time, resulting
in different behaviors, such as the ability to metastasize.83
Third, tumor profiles can changewith treatment as those cells
with targeted features are destroyed by chemotherapy and
others without are left behind to develop more genetic
alterations.84 A static sample of tissue from a single point
in time is not able to reflect these ongoing and dynamic
changes. Furthermore, if repeat tissue is needed for analysis, it
involves an invasive procedure with inherent complications
that can impact patients’ care and treatment.
Development of a “liquid biopsy” is an ongoing research
topic that is making considerable progress in recent years as
amplification technologies are rapidly improving. The goal is
to discover a substrate that is sensitive enough to detect the
presence of early CRC, but also specific enough to discriminate
from other adenocarcinomas, provide molecular profiling of
the tumor to direct targeted therapies and assess for re-
sponses to treatment, offer prognostic information about the
risk of recurrence and response to therapy, and can be drawn
repeatedly over the course of treatment with little to no risk.
While we have not yet identified the ideal candidate, several
targets are showing promise.
Proteins circulating in the serum have long been used as
biomarkers, including CEA and CA 19–9. These tests have the
benefit being easily reproducible, but are not very sensitive or
specific for diagnosing CRC and provide only rough
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prognostication.85 They also do not offer any guides to treat-
ment, but do tend to correlate with disease progression or
response.86 The potential pool of proteins fromwhich to draw
a biomarker is endless, but one candidate, Rab27b, has shown
promise. In a recent publication, this GTPase involved in
regulating secretory pathways and oncogenesis was shown
to have elevated expression in tumor when compared with
adjacent normal tissues, and high levels correlatedwith serum
CEAelevations, lymphnodemetastases, andTNMstage, aswell
as overall survival rate in a cohort of 116 CRC patients.87
Further work will needed to be done to determine if serum
expression of Rab27b correlates or offers improved sensitivity
and specificity beyond current biomarkers. Rather than inves-
tigate known oncogenic proteins de novo in each cancer type,
another strategy could be a more powerful way to identify
candidate proteins. Surinova et al (2015) used a screening
method to identify candidate glycoprotein biomarkers from
tumor epithelia, then screened selected proteins in the plasma
of CRC patients to identify those that reached the circulation.
Overall, 88 proteins were identified and 70 fulfilled validation
criteriawith an independent cohort; further consensus testing
identified 5 proteins that consistently predicted disease and
performed better than CEA in diagnosing CRC, evenwhen used
together with the CEA.88
MicroRNA (miRNA) is another area of active investigation
as a source of biomarkers for CRC. miRNA is small, noncoding
single strands of RNA that are thought to play a role in
posttranscriptional regulation of gene expression and are
dysregulated in CRC.89 Several candidates have been identi-
fied, includingmiRNA-375, miRNA-183, andmiRNA-211 that
correlate with detection, recurrence, or prognosis.89–91 How-
ever, the understanding of these biomarkers and their native
functions is poorly understood. In addition, testing for these
substances is highly variable in commercially available kits,
calling into question the reproducibility of using these small
molecules in the clinical setting.92 Furthermore, proteins and
miRNA will never have the potential to provide meaningful
genetic information about the tumor and its response to
treatment, limiting the applicability of these biomarkers.
Perhaps the area showingmost potential is in the detection
and analysis of circulating DNA and circulating tumor cells
(CTCs). Circulating cell-free DNA (cfDNA) is thought to arise
from both normal and tumor cells as a result of normal
processes as well as apoptosis and necrosis.93 Amplification
of cfDNA has been increasingly used to diagnose fetal genetic
abnormalities in high-riskwomen,with positive testswarrant-
ing more invasive diagnostic procedures, and these cfDNA
screening tests have also identified new incidental malignan-
cies in the mother due to their high sensitivity.94 Levels of
serum cfDNA been shown to correlate with prognosis in
metastatic CRC, and it also has the potential to be a source
for detection of various genetic mutations, with a high concor-
dance of KRAS mutations when compared with standard
techniques.93,95 Evaluating the level and pattern of methyla-
tion in cfDNA samples has also been shown to be sensitive for
detecting CRC, especially for stage IV disease.96,97 CTC can also
be a highly sensitive and specific biomarker and provide
specific genetic information about both the tumor and its
response to treatment. Using enrichment and depletion tech-
niques, CTC canbe isolated anddetected by targeting their cell-
surface markers, such as CK20, so that further analysis can be
performed.98 The discordance between CTC and primary
tumor was low for both KRAS and KRASmutations.99 Further-
more, patients with known KRAS mutations in CTC were
shown to have poor outcomes when treated with anti-EGFR
therapy, the same as if primary tumor testing occurred.100
Conclusion
As we approach an era of personalized medicine, the impact
of each individual tumor cell and each person’s unique
genetic profile will become increasingly important. Our
understanding of the utility of these mutations is only in its
infancy. We currently use only CEA as a routine serum
biomarker, and it has significant limitations. While we are
fairly good at identifying heritablemutations, several persons
with a strong family history do not have any mutation we
currently test for, suggesting that there are still many more
genes with influence over the development of CRC. Our
understanding of how tumor genetic mutations can predict
response to therapy and oncologic outcomes is poor and
improvements in this arena could have a huge impact on
our everyday practice and advances here will become pro-
gressively more valuable. Furthermore, the discovery of a
“liquid biopsy” to diagnose, predict response, and prognosti-
cate outcomes would be monumental, not only from a
treatment standpoint, but from a quality of life and comfort
standpoint of our patients. The future in biomarker under-
standing is wide open and there remains much to be learned.
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